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ABSTRACT
With more than 130 people dying daily, 47,000 overdose-related deaths per year,
and $55 billion in societal costs, the opioid epidemic is producing widespread,
catastrophic consequences on the population and healthcare system. Healthcare
providers report high concern and lack of confidence that their training prepared them
adequately to manage chronic pain with opioid therapy. There is insufficient evidence
determining whether educating healthcare providers on opioid prescribing guidelines
leads to improved knowledge, confidence, and a decrease in concern. The aim of this
study is to assess the knowledge, confidence, and concern of 2020 Bethel University
physician assistant (PA) students of opioid prescribing before and after completing a
series of opioid prescribing training modules created by Centers for Disease Control and
Prevention (CDC). 28 Bethel University PA students were included, with one
participant's data being removed due to not completing the post-assessment. Results
demonstrated statistically significant increases in knowledge (pre-assessment 12.26 ±
2.25, post-assessment 14.96 ± 1.58, t(26) = 6.55, p = 0.00) and confidence (preassessment 3.70 ± 2.00, post-assessment 5.89 ± 1.42, t(26) = 4.73, p = 0.00), and
decrease in concern (pre-assessment 7.18 ± 1.9, post-assessment 5.52 ± 1.78, t(26) = –
4.60, p = 0.00) regarding appropriate prescribing of opioids. These findings suggest that
CDC’s opioid prescribing training modules are effective in educating PA students,
improving their knowledge, confidence and decreasing concern when prescribing
opioids.
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Chapter 1: Introduction
Introduction
Thirty years ago, amidst the burgeoning pain epidemic when pain was regarded as
the “fifth vital sign,” the addictive nature of pharmaceutical-grade opioids was not fully
understood (Maxwell, 2011). Since that time, opioid prescriptions by healthcare
providers have increased in strength and duration, which has become a factor that has led
to the current opioid crisis in the United States (Shah et al., 2017; Martin et al., 2011;
Hoots & Seth, 2018). As of 2017, opioid misuse in the United States has been designated
a public health emergency (US Department of Health and Human Services, 2017).
Opioid misuse and abuse may often progress to addiction and the creation of widespread
problems on the healthcare system and the lives of patients (Seth et al., 2018). These
problems are adversely affecting large portions of the US, and statistics illustrate the
problem is not slowing down (Hoots & Seth, 2018; Birnbaum et al., 2011).
Healthcare providers are presented with difficult and unexpected challenges when
prescribing opioids: including the daunting task of discerning whether patients are drug
seeking or actually in need of opioids (Fields, 2011). This thesis presents current opioid
epidemiology, the pathology behind opioid addiction, and healthcare provider opioid
prescribing knowledge. The researchers will then evaluate physician assistant (PA)
students' knowledge, confidence, and concern regarding proper opioid prescribing
practices before and after completing a series of training modules based on opioid
prescribing guidelines created by the Centers for Disease Control and Prevention (CDC).
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Background
Opioid misuse and abuse are significant issues in the US both economically and
on healthcare providers (Birnbaum et al., 2011). In 2007, the plight of opioid abuse
subjected the US to an estimated $55.7 billion in societal costs (Birnbaum et al., 2011).
The US Department of Health and Human Services (2018) estimates that 130 or more
people die in the US every day from an opioid overdose. The Morbidity and Mortality
Weekly Reports (MMWR), published by CDC, emphasize the extent and reality of the
opioid crisis. Figure 1, from MMWR, illustrates that in 2016, an estimated 42,249
opioid-related overdose deaths occurred, and in 2017, opioid-related overdose deaths rose
to an estimated 47,600 (Scholl et al., 2018; National Institute on Drug Abuse, 2018).
Figure 1
US National Drug Overdose Deaths Involving Opioids

Note. Number of deaths among all ages by gender; 1999-2017 estimated in thousands.
Adapted from “Opioid Death Rates,” in National Institute on Drug Abuse, by Morbidity
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and Mortality Weekly Reports, CDC Wonder, 2018. Retrieved March 13, 2019 from
(https://www.drugabuse.gov/related-topics/trends-statistics/overdose-death-rates). In the
public domain.
Approximately 40% of these opioid-related deaths are due to prescription opioids
(Hoots & Seth, 2018). Figure 2, from MMWR, depicts the prescription opioid-related
overdose deaths over the last 18 years.
Figure 2
US National Drug Overdose Deaths Involving Prescription Opioids

Note. Number of deaths among all ages, 1999-2017; estimated in thousands. Adapted
from “Opioid Death Rates,” in National Institute on Drug Abuse, by Morbidity and
Mortality Weekly Reports, CDC Wonder, 2018. Retrieved March 13, 2019 from
(https://www.drugabuse.gov/related-topics/trends-statistics/overdose-death-rates). In the
public domain.
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Traditionally, opioid prescriptions have been used for the treatment of pain, but
due to the nature of opioids having an imitating effect on endorphins, patients medicated
with opioids are at a heightened risk of abuse, misuse, and addiction (Chahl, 1996).
Furthermore, opioids have been prescribed to reduce anxiety and be used as a mild
sedative (Fields, 2011). When patients take opioids long-term (continued use one year
after prescription) for pain management, they are at greater risk of developing a tolerance
to the opioid analgesic effects (Kosten & George, 2002). Once tolerance to the opioid’s
analgesic effects emerges, the brain and body demand increasingly higher doses to attain
identical results as the previous smaller doses, resulting in a vulnerable state of chemical
dependence (Kosten & George, 2002). Chemical dependency evolves into a physiologic
and psychologic response, which manifests as overwhelming withdrawal symptoms if the
drug is taken away (Kosten & George, 2002). Often, opioid dependence results in
individuals starting to use their prescription outside of its intended use (misuse) (Kosten
& George, 2002). The dependence process can then lead to the development of
addiction, when the drug becomes a physiologic need (Kosten & George, 2002).
To date, opioids are still “the most potent and reliable analgesic agents” (Fields,
2011, para. 1). While no longer considered the first line prescription for chronic pain,
opioids often are designated for acute pain (Fields, 2011). Chronic pain is medically
described as unremitting or intermittent pain persisting for three months or longer
(Treede et al., 2015). Whether acute or chronic, pain disrupts and weakens overall
physical, mental, social, and spiritual well-being. "Chronic pain is a significant global
public health concern associated with risk of depression, anxiety, unemployment, and
opioid abuse.” (Webster et al., 2017, para. 1). Chronic pain can be devastating; one
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estimate reported that 61% of patients with diagnosed chronic pain were unable attend
work or perform job duties due to effects of their persistent pain (Breivik et al., 2006).
Additionally, 60% of patients with chronic pain visited a healthcare provider more than
once in the past six months, and 40% of patients with chronic pain thought their pain was
inadequately managed (Breivik et al., 2006).
In 2011, the Institute of Medicine estimated at least 100 million American adults
suffer from chronic pain; excluding those in prison, the military, or long-term care
facilities (Institute of Medicine, 2011). Furthermore, an analysis performed by the
National Center for Complementary and Integrative Health approximates that at least
25.3 million American adults suffer daily with some manner of chronic pain (Nahin,
2015). The more frequent and commonly assessed categories of non-cancer chronic pain
conditions typically are associated with joint pain (e.g., osteoarthritis), back and neck
spinal pain (e.g., radiculopathies), recurring headaches, and neuropathies (Tsang et al.,
2008). Several studies argue that opioid misuse is more likely to occur in patients who
take opioids continually and for extended periods of time for managing chronic pain;
although, the correlation between protracted use and misuse of opioids as of yet is
circumstantial (Fields, 2011).
In 2016, CDC released guidelines on opioid prescribing in an effort to guide the
clinical practice of healthcare providers (Dowell et al., 2016). CDC’s guidelines include
recommendations on opioid prescription type (immediate-release vs. extended-release),
the dosage in Morphine Milligram Equivalents (MME), and duration of opioid use
(Dowell et al., 2016). The 2016 CDC guidelines are supported by evidence that opioid
addiction risk is at its lowest when treating chronic pain patients who were previously
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opioid drug-naive (Fields, 2011). Additionally, CDC provides recommendations to
healthcare providers on how to discuss goals of opioid treatment with patients as well as
when and how to discontinue opioid use (Dowell et al., 2016). While CDC guidelines
provide healthcare providers with recommendations for safer and appropriate methods
and strategies for prescribing opioids, research has demonstrated that prescribing habits
have not been in line with the 2016 CDC guidelines (Dowell et al., 2016; Shah et al.,
2017). Specifically, data collected by Shah, et al. (2017) found when patients were
prescribed opioids for longer durations and at higher MME doses than CDC
recommendations, patients were at higher risk for prolonged, chronic opioid use.
Because research has shown long-term opioid treatment risk factors are related to dosage
and length of prescription, healthcare providers may be contributing to the opioid
epidemic with current prescribing practices (Shah et al., 2017).
Providers face inordinate amounts of pressure to provide appropriate treatment
and sufficient pain relief, which is regarded as a standard of care and, in some states,
required by law (Fields 2011). This standard has created what many healthcare providers
feel is a dichotomic, moral quandary (Fields, 2011; Rosenblum et al., 2008). On the one
hand, prescribers know about the possible serious and sometimes fatal side effects of
opioids, but on the other, they are required by conscience and, in many states, by law to
help alleviate their patients’ suffering (Fields 2011). When physicians, PAs, advanced
practice nurses, and registered nurses working primarily in primary care were polled, the
majority expressed that they were not confident in chronic pain management (Pearson et
al., 2017). Additionally, 63% of physicians, working in family medicine, internal
medicine, and pediatrics, surgeons, and nonsurgical specialists, reported they did not
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believe they received adequate instruction and training for appropriately managing
chronic pain (Darer et al., 2004).
Inadequate opioid prescribing education might also lead to diminished confidence
in providers’ opioid prescribing abilities. However, structured education regarding
opioid prescribing recommendations may combat the lack of healthcare provider
confidence and reduce the incidence of long-term opioid use. Chronic opioid use may
only progress as the US population continues to age, and the need for chronic pain
treatment will most likely continue to grow (Darer et al., 2004).
Problem Statement
Healthcare providers report not feeling confident and that their training did not
prepare them adequately to manage chronic pain and prescribing opioids (Darer et al.,
2004; Pearson et al., 2017). Healthcare providers also communicated that opioid abuse
and addiction was a concern when prescribing opioids (Pearson et al., 2017). There is
insufficient evidence determining whether educating healthcare providers with CDC’s
opioid prescribing guidelines leads to improved knowledge.
Purpose
The objective of this study is to assess the knowledge, confidence, and concern of
Bethel University PA students in prescribing opioids for the treatment and management
of chronic pain conditions by utilizing CDC’s opioid prescribing module
training. Research about PA students’ knowledge, confidence, and concern in
prescribing opioids in their didactic and clinical training is lacking.
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Research Questions
Therefore, the following research questions will be investigated and analyzed in
this study.
1.

How is PA student knowledge increased following completion of the CDC
opioid prescribing module training?

2.

How is PA student opioid prescribing confidence increased following
completion of the CDC opioid prescribing module training?

3.

How is PA student concern affected with respect to opioid prescribing
before and after completion of the CDC opioid prescribing module
training?

Significance of the Problem
The rates of opioid prescriptions in the United States have been declining in
recent years, but this is not consistent across the country (Hoots & Seth, 2018). Large
portions of the south and northeast US have seen dramatic increases in both the number
and MME dosage of opioid prescriptions as the national rates have declined (Hoots &
Seth, 2018). One trend that is consistent nationwide is the increasing duration of opioid
prescriptions (Hoots & Seth, 2018). Over the course of the previous 12 years, the
average opioid prescription duration has increased from 13.3 days to 18.3 days while
rates of shorter prescriptions have decreased (Hoots & Seth, 2018). This trend
demonstrates that fewer opioid prescriptions are being taken for short durations and the
average length of opioid prescriptions is continuing to increase in duration.
A majority of physicians, PAs, and nurse practitioners do not feel confident or
prepared to prescribe opioids for chronic pain (Pearson et al., 2017). Additionally, 55%
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of these same respondents report not following a protocol when prescribing opioids.
However, when respondents stated they adhered to a recommended opioid protocol, the
result correlated with having increased confidence in administering and regulating opioid
treatment to patients with chronic pain (Pearson et al., 2017).
Definition of Terms
The terms listed below are important to know regarding the research presented in
this study.
Acute Pain: Transient pain with a duration less than 3 months (Treede et al, 2015).
Abuse: “Intentional, non-therapeutic use of a drug product or substance, even once, to
achieve a desired psychological or physiological effect” (US Food and Drug
Administration, 2017).
Chronic Pain: “Persistent or recurrent pain lasting longer than 3 months” (Institute of
Medicine, 2011; Treede et al., 2015).
Dependence: “A state that develops as a result of physiological adaptation in response to
repeated drug use, manifested by withdrawal symptoms after abrupt discontinuation or a
significant dose reduction of a drug” (US Food and Drug Administration, 2017).
Long-term use: “Continued use of opioids greater than one year after initial prescription”
(Shah et al., 2017).
Misuse: “Use of a medication (for a medical purpose) other than as directed or as
indicated, whether willful or unintentional, and whether harm results or not” (Katz et al.,
2007).
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Morphine Milligram Equivalents: “Standard value based on morphine and its potency
which helps determine the potency of opioid doses and is useful if converting from one
opioid to another” (Hoots & Seth, 2018).
Opioids: A class of legal and illegal drugs derived from morphine (an opiate) and are
commonly prescribed to treat pain (e.g., heroin, oxycodone, hydrocodone, methadone,
and fentanyl) (Rosenblum et al., 2008).
Conclusion
The current prevalence of opioid abuse and rising overdose rates occurring in the
US demands a requirement for appropriate and thorough training and education for
healthcare providers. CDC has released guidelines to give providers a structured plan on
how to prescribe opioids safely and effectively as well as how to discuss opioid use
related risks and benefits with patients. CDC guidelines recommend shorter opioid
durations and lower MME doses for prescribing opioids to patients, which have both
been found to reduce unnecessary, prolonged opioid use (Martin et al., 2011; Shah et al.,
2017). However, it is currently unclear how many healthcare providers have
implemented CDC guidelines, suggesting the need to evaluate training methods for
healthcare providers.
The literature review in the following chapter will provide an introduction and
overview of opioids, including their mechanism of action, how opioids cause tolerance
which leads to chemical dependence and addiction, and to identify the different classes of
opioids. The upcoming chapter will then present current trends of opioid prescribing and
overdose deaths in the US and provide an overview of the topics and strategies covered in
the 2016 CDC guidelines and recommendations for prescribing opioids for chronic pain.
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Finally, an account on the current literature relating to the knowledge, confidence, and
concern healthcare providers have when prescribing opioids will be addressed.
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Chapter 2: Literature Review
Introduction
Opioids are a powerful, dynamic class of drugs which are prominent in the role of
carefully considering and deciding between both short and long-term pain management
strategies (Rosenblum et al., 2008). Opioids are essentially chemical molecules that
couple with several distinct neurological binding sites (receptors), and when bound to
said receptors, block the transmission of pain and cause a state of pleasure and happiness,
known as euphoria (Fields, 2011). Opioids can be used safely and effectively by
providers to help patients, yet they also carry potential serious side effects, including their
highly addictive nature and risk of overdose (Kosten & George, 2002; Rosenblum et al.,
2008; Webster et al., 2017). Opioids, specifically illicit opioids, are the leading cause of
overdose-related fatalities in the US (Hoots & Seth, 2018). While overdoses and
addictions due to opioid prescriptions are less than half of the overall figures, these
overdoses and addictions are more easily tracked and regulated than non-prescription
opioids (Hoots & Seth, 2018).
Many providers still express uncertainty and worry as far as prescribing opioids to
their patients, making provider worry and uncertainty a valid concern (Darer et al., 2004;
Pearson et al., 2017). From 2009 to 2016, deaths resulting from prescription opioid
overdose have risen by 18% (Atluri et al., 2018). Prescribers are also influenced by what
is known as “hidden curriculum,” or what providers are learning from society and
influencers around them – both medical and non-medical (Fields, 2011). Studies have
found that many opioid prescriptions are written incorrectly, causing either inadequate
pain management or increased side effects including drug dependency and addiction
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(Webster et al., 2017). As mentioned in chapter one, opioid misuse, abuse, and addiction
are creating widespread problems on the US healthcare system and in the lives of patients
(Seth et al., 2018). To fully conceive the reasons why opioid dependency is so rampant
and how the addiction develops, it is necessary to have a thorough understanding of the
neurophysiological operations and mechanics of opioids within the body and how the
pathology of addiction develops (Kosten & George, 2002). The remaining sections in
this chapter will examine the neurobiology of opioids, pathology of drug tolerance,
dependence, and addiction, and review the current literature on opioid prescribing and
healthcare provider opioid knowledge in the US.
Opioid Mechanism of Action
With respect to biochemical interactions, chemical make-up, and general function
within the human body, opioids are grouped into two broad, nonspecific categories called
endogenous and exogenous opioids. Endogenous opioids, also known as endorphins,
enkephalins, and dynorphins, are naturally occurring neurotransmitters – messenger
molecules that relay and transmit signals – produced in the pituitary gland in the brain
and adrenal medulla, respectfully (Sprouse-Blum et al., 2010). These endogenous
peptides are released in response to stimuli such as pain, stress, sexual activity, fear, and
during and after prolonged exercise (Sprouse-Blum et al., 2010). Endorphins and
enkephalins, specifically, play a role in sustaining equilibrium with nutrient metabolism,
aid with cardiovascular modulation, and are the natural mediators of pain relief. These
neuropeptides essentially provide the human body with a way to adapt to extrinsic factors
and stimuli that the body is consistently exposed to (Chahl, 1996). Exogenous opioids
mimic the effects of endogenous opioids in many ways, but primarily to mediate the
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body’s physiologic pain response. However, these exogenous chemicals are artificial and
pharmacologically modified opioids with stronger degrees of potency to treat pain in
clinical situations (Chahl, 1996).
Most opioids, whether endogenous or exogenous, bind to three distinct types of
cell membrane neurotransmitter receptors; mu (μ), delta (δ), and kappa (κ) (Pasternak,
1993). All three receptors types are widely disseminated throughout the central nervous
system (CNS), the brain and spinal cord, and the peripheral nervous system (PNS),
peripheral nerves and nerve cells located outside the brain and spinal cord. In the brain,
opioid receptors are most abundant in the ventral tegmental area (VTA), tractus solitarius,
periaqueductal gray area (PAG), thalamus, hippocampus, and cerebral cortex (Kosten &
George, 2002; Yaksh, 1997). In the spinal cord, opioid receptors are distributed evenly,
but with a higher concentration located in the substantia gelatinosa (SG) (Trivedi &
Shaikh, 2007). When activated by opioids, all three receptor types elicit similar effects
with varying degrees of each; however, at the same time, they also operate distinctly from
one another in various, unassociated biological functions (Pasternak, 1993). The shared
attributes of μ, κ, and δ receptors are predominantly involved in the role of analgesia or
inhibiting or suppressing an organism’s response to pain (Pradhan et al., 2012). In
addition to analgesia, all three receptors types induce mild to intense euphoric effects and
neuronal activity inhibition. The degree of euphoria generated depends on which of the
three receptor types are being stimulated, while the degree of analgesia is contingent on
dosage, potency, and whether the opioid is synthetic vs non-synthetic (Pradhan et al.,
2012). When stimulated by exogenous opioids, μ receptors elicit various significant CNS
and PNS effects. The CNS effects include powerful inhibition of acute pain, substantial

24

euphoria, stress regulation, respiratory depression, sedation, urinary retention, decreased
gastrointestinal motility (causing constipation), pruritus, urticaria, mild to moderate
reduction in heart rate, and physical dependence (Al-Hasani & Bruchas, 2011). Kappa
receptors, when activated, primarily regulate mood, stress, consciousness, feeding, gut
motility, and spinal analgesia. But when stimulated by moderate to high dose of
exogenous opioids, κ receptors may cause pupillary constriction, diuresis, sedation, and
dysfunctional effects such as dysphoria and psychomimetic effects, including
hallucinations, delirium and/or delusions (Trivedi & Shaikh, 2007; Pradhan et al., 2012).
While having positive effects in powerful spinal and supraspinal analgesia, δ receptors
are distinct from κ and μ receptors in respect to opioid type selectivity. In addition, δ
receptors potentially elicit distinct negative effects such as hypotension and decreased
brain and myocardial oxygen demand when activated (Trivedi & Shaikh, 2007). Mu
receptors are considered the most clinically relevant target for acute analgesia and yield
the most significant benefits, but also pose a greater risk for deleterious effects (Pathan &
Williams, 2012).
Opioid Pathology: Tolerance, Dependence & Addiction
Acute and chronic pain can be considerably debilitating at times; thus, warranting
pharmacologic intervention (Chahl, 1996). Exogenous opioids, such as the prototypic
opiate, morphine, or synthetic types like fentanyl, have been the means and cornerstone
for analgesic management in patients; more commonly for acute pain or chronic pain
with moderate to severe intensity (Savage et al., 2008). Overtime, with continuous
exposure to the same or similar drugs, patients undergo an adaptive process called
tolerance (Dumas & Pollack, 2008; Savage et al., 2008). Opioid tolerance develops
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rapidly and occurs when the μ opioid receptors no longer respond to the repeated
stimulation of opioids (Dumas & Pollack. 2008). Physiologically, the μ receptors have
acclimated to the same chemical signal and become desensitized to repeated triggers.
The opioid receptor system is exceptionally unrivaled to any other receptor system in the
body to the degree that desensitization occurs at a quicker rate (Savage et al., 2008). An
opioid, when bound to μ receptors will trigger an enzyme called adenylate cyclase that
fires impulses along neurons to achieve the desired effect. When desensitized, the
receptor demands extra stimulation in order to trigger adenylate cyclase to achieve the
same effect be it analgesia or euphoria (Dumas & Pollack, 2008). Therefore, higher and
higher doses of prescription opioid are necessary to maintain analgesic effects long-term
(Savage et al., 2008). Opioid tolerance is regarded as a pivotal step in the direction
toward chemical dependence and addiction; although, tolerance is neither a state nor
indicator of dependence or addiction (Savage et al., 2008).
Despite the tremendous pain relief benefits that opioid therapy produces, as
discussed previously, these drugs not only act on individual pain receptors, but they also
produce a significant synergistic effect in the thalamus, hippocampus, and midbrain
where the mesolimbic reward circuit operates (Kosten & George, 2002). When
stimulated through opioid binding, the reward circuit signals the cells in the VTA to
release dopamine, whose function is that of a hormone and neurotransmitter. Dopamine
subsequently stimulates the nucleus accumbens (NAc) in the prefrontal cortex (PFC)
giving rise to emotions of euphoria and well-being. Often, when exogenous opioid
binding is involved, euphoric feelings may reach unnatural, elevated levels (Kosten &
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George, 2002). Figure 3 portrays the areas associated with the endogenous mesolimbic
system and how they are connected.
Figure 3
The Mesolimbic Reward System

Note. The ventral tegmental area (VTA) contains dopamine producing cells. Dopamine
is shuttled to the nucleus accumbens (NAc) where feelings of pleasure and well-being are
produced. The prefrontal cortex (PFC) is the neurotransmitter feedback hub which
communicates with the VTA to either upregulate or downregulate production of
dopamine depending on stimulus. The locus coeruleus (LC) is involved in chemical
dependence and will be explained later in further detail. These illustrated areas are
housed within the midbrain regions of the hippocampus and thalamus. From “The
Neurobiology of Opioid Dependence: Implications for Treatment,” by Kosten, T., &
George, T. (2002). Science & Practice Perspectives, 1(1), p. 13-20.
doi:10.1151/spp021113. In the public domain.
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Kosten & George (2002) further explain that the PFC naturally creates a negative
feedback loop with the VTA to cease dopamine production when there is excess opioid
receptor stimulation. As a result, this homeostatic process enables one’s conscious ability
to refrain from perpetuating the urge to seek pleasure “through actions that may be unsafe
or unwise” (Kosten & George, 2002; para. 14). However, when exogenous opioid
misuse occurs, an over-surge of dopamine interrupts the PFC-VTA-feedback loop
rendering it nonfunctional which is apparent in individuals who develop a chemical
addiction.
Dopamine is heavily involved in regulating movement, motivation, attention,
learning, focus, executive functions, and emotions including pleasure and well-being
(Kosten & George, 2002). Homeostatic modulation of dopamine is essentially what
drives the human body’s most simple goal-directed and reward-motivated behaviors such
as appetite, sleep, cognition, and sexual reproduction. Additionally, dopamine plays a
role, to some extent, in mediation of heart rate, kidney function, blood vessel function,
and lactation (Kosten & George, 2002). Endorphins, as mentioned earlier in this chapter,
also have neurostimulatory effects in this process, but these neuropeptides are released in
appropriate amounts and function in healthier processes by not overstimulating opioid
receptors to create an overproduction of dopamine and thus shutting down the PFC-VTAfeedback loop (Chahl, 1996; Kosten & George, 2002).
Conversely, dysregulation of the endogenous reward system occurs when opioid
tolerance develops into a chemically dependent state such as the physical necessity of
daily opioid use to avoid distressing withdrawal symptoms (Kosten & George, 2002).
The pathology of this drug dependence lies in the dysfunction of synergistic neural
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circuits in various locations of the CNS (Chahl, 1996; Savage et al., 2008). In the
brainstem, the LC is the primary location associated with the release of the
neurotransmitter norepinephrine (NE) (Kosten & George, 2002). In general, NE is
responsible for regulatory operations such as arousal, alertness, attention/focus,
respiration, and blood pressure (Savage et al., 2008). When individuals experience
withdrawal symptoms to opioids, NE becomes involved as a primary culprit (Savage et
al., 2008). “Opioid withdrawal is one of the most powerful factors driving opioid
dependence and addictive behaviors” (Kosten & George, 2002, para. 8).
Opioids not only activate the VTA, but they also activate the LC resulting in
suppression of NE release. When suppression of NE release occurs for extended periods,
the result is the manifestation of symptoms such as hypotension (low blood pressure),
bradypnea (reduced breathing), bradycardia (reduced heart rate), and drowsiness (Kosten
& George, 2002). In instances of opioid overabundance in the mesolimbic system and
LC, excessive suppression of blood pressure and respiration can cause death – common
occurrence of opioid overdose whether intentional or not (Kosten & George, 2002;
Savage et al., 2008).
Upon reaching the imperceptible juncture of opioid tolerance, or when opioid
intake is temporarily ceased, the inadequate μ receptor stimulation, or the complete
absence thereof, suppresses the LC. This results in a surge of NE to flood the CNS and
PNS causing jitters, muscle cramps, diarrhea, confusion, delirium, and anxiety (Kosten &
George, 2002). Reduction in opioid quantity also affects the individual’s dopamine
release which rapidly diminishes euphoric effects and negatively impacts and
dysregulates other life-sustaining, goal-directed behaviors – appetite, sleep, motivation,
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cognition, etc. (Hyman & Malenka, 2001; Kosten & George, 2002). Consequently,
psychological withdrawal symptoms such as distress, irritability, restlessness, anxiety,
and depression all develop alongside physical withdrawal symptoms – muscle cramps,
nausea, vomiting (Hyman & Malenka, 2001). With prolonged, repetitive use combined
with intermittent cycles of withdrawal, this syndrome of physiologic and psychologic
impairment chemically shifts the wiring in the VTA and thalamus into survival mode
creating insatiable cravings, and a compulsive urge to reinstate the original stimulus. At
this point, the compulsivity and insatiable cravings become more than one can control,
mentally and physically, resulting in a state far beyond dependence. Eventually, this
process evolves into a physical and psychological state of imperative need for the
substance in order to function normally; thus, chemical addiction is created (Hyman &
Malenka, 2001). Kosten & George (2002) go on to explain that:
...the pleasure derived from opioids’ activation of the brain’s natural reward
system promotes continued drug use during the initial stages of opioid
addiction. Subsequently, repeated exposure to opioid drugs induces the brain
mechanisms of dependence, which leads to daily drug use to avert the unpleasant
symptoms of drug withdrawal. Further prolonged use produces more long-lasting
changes in the brain that may underlie the compulsive drug-seeking behavior and
related adverse consequences that are the hallmarks of addiction (para. 13).
Classes of Common Pharmacologic Opioids
Prescription opioids, also called pharmacologic opioids or narcotics (a legal term
denoting illicit opioids), are categorized by different classes based on purity (Evans,
2004). Opium alkaloids, chemical compounds extracted from seeds of the opium poppy
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plant (Papaver Somniferum), are the chemical derivatives of what we know today as
pharmacologic opioids (Evans, 2004). Morphine and codeine are considered the
naturally occurring exogenous compounds that are termed opiates. Prescription opioids,
on the other hand, are not naturally occurring, but rather formulated and enhanced
compounds classified as semi-synthetic or fully synthetic opioids (Chahl, 1996).
Morphine has become the standard baseline measurement for proper dosing
comparisons and illustrates the relative strength of various opioid medications. Morphine
Milligram Equivalents (MME) is considered the standard value based on potency (CDC,
2017). MME values are a method for differentiating the common opioids in order to
assess how each are implicated in opioid-related overdose occurrences. The most
common prescription opioids with associated trade names listed in MME potency – least
to most potent – respectively, are as follows: meperidine (Demerol), tramadol (Ultram),
hydrocodone (Hysingla, Zohydro), hydrocodone & acetaminophen (Lorcet, Lortab,
Norco, Vicodin), oxycodone (Roxicodone, OxyContin, Oxecta,), oxycodone &
acetaminophen (Percocet, Endocet, Roxicet), oxycodone & naloxone (Targiniq),
diamorphine (Heroin), methadone (Dolophine, Methadose), hydromorphone (Dilaudid,
Exalgo), buprenorphine (Subutex), and fentanyl (Actiq, Duragesic, Fentora) (Von Korff
et al., 2008; The Royal College of Anaesthetists, 2018; CDC, 2017).
Opioid Prescribing Trends
Over the past 12 years, CDC has reported the overall number of opioid
prescriptions and MME dosages are in decline in the United States (Hoots & Seth,
2018). Specifically, since 2006 the rates of opioid prescriptions have decreased from
72.4 per 100 persons to 58.5 per 100 persons in 2017 (Hoots & Seth, 2018). Similarly,
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since 2006 opioid MME doses greater than or equal to 90 have declined from 11.5 per
100 persons to 5.0 per 100 persons in 2017 (Hoots & Seth, 2018). However, while the
overall number of opioid prescriptions and MME dosages have declined since 2006, the
number of opioid prescriptions has risen for prescriptions longer than 30 days (Hoots &
Seth, 2018). This signifies that medical providers are prescribing opioids for patients for
longer periods of time. Rates of prescribing these longer courses of opioids have
increased from 17.6 to 24.6 per 100 persons from 2006 to 2017. The data does show,
however, that the 2017 estimate of 14.6 is down from its peak in 2015 (Hoots & Seth,
2018). The average length of an opioid prescription has steadily increased from 13.3
days in 2006 to 18.3 days in 2018 and this year to year increase does not appear to be
slowing (Hoots & Seth, 2018). In response to longer opioid prescription course lengths,
the rate of opioid prescriptions of less than 30 days have steadily decreased from 54.7 to
33.9 per 100 persons between 2006-2017 (Hoots & Seth, 2018). These findings suggest
that while overall rates of opioid prescriptions are declining, individuals who are being
prescribed opioids are taking them for longer durations, resulting in an increased risk of
potential long-term use.
While there has been a drop in the overall rate of opioid prescriptions in recent
years, the 2017 national rate of opioid prescriptions was still very high (58.5 prescriptions
per 100 persons), with some areas of the United States varying greatly from the national
average (Hoots & Seth, 2018). Specifically, in Alabama (107.2), Arkansas (105.4),
Tennessee (94.4), Mississippi (92.9), and Louisiana (89.5), the rates of opioid
prescriptions per 100 persons are markedly higher than the 2017 national average,
including the 2006 national average of 72.4 per 100 persons (Hoots & Seth, 2018). This
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data suggests a larger concern for opioid prescription misuse and abuse. Furthermore, a
similar trend is visible in opioid MME dosages of greater than or equal to 90 for
Delaware (11.0), Utah (8.4), Alaska (8.3), Vermont (8.1), and New Hampshire (8.0),
which demonstrate the highest rates per 100 persons, well above the national average of
5.0 MME (Hoots & Seth, 2018). This data portrays clearly the opioid epidemic and its
continued effects across large segments of this country.
To further identify the factors influencing long-term opioid use, CDC analyzed
patient chart data to investigate any associations (Shah et al., 2017). In studying
retrospective patient chart reviews, three associations appeared. Doses of greater than
700 MME, receiving a third opioid prescription, and opioid use longer than 10-30 days
showed the greatest likelihood to have prolonged opioid use (Shah et al., 2017). Shah et
al. (2017) found 70% of patients were prescribed an opioid regimen for less than or equal
to seven days, and seven percent for longer than 31 days. Furthermore, the data reported
by Shah et al. (2017), also demonstrated two escalation points at both six- and 31-day
prescription lengths, displaying spikes in increased likelihood of continued use after each
time point. These findings support the 2016 CDC guidelines on opioid use, which
recommend prescribing the shortest course of opioid as possible, with less than seven
days as the goal and less than three days as an ideal length of treatment (Dowell et al.,
2016).
Moreover, research has suggested that MME amounts prescribed also influence
potential long-term opioid use, both in total and daily equivalents (Shah et al., 2017). As
previously stated, Shah et al. (2017) found a prescription total of 700 MME posed a high
probability of continued long-term use, while Martin et al. (2011) found a MME daily
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dose greater than 120 MME was associated with opioid use for longer than 90
days. These findings support CDC recommendations that MME dosages should be less
than 50 MME as often as possible (Dowell et al., 2016). Providing healthcare providers
with adequate training on appropriate dosages and prescription lengths may aid in
combating the on-going opioid crisis and reduce the risk of long-term opioid use.
Overdose Deaths
As the opioid epidemic has proliferated across the country a consistent rise in
overdose deaths has occurred. The incidence of opioid overdoses from any opioid has
doubled from 2010 (6.6 per 100,000 persons) to 2016 (13.3 per 100,000 person)
(Hedegaard et al., 2017) seeing the starkest increase since 2013 (7.9 per 100,000
persons). The two opioids most commonly used in opioid-related overdose deaths, and
which have been driving the recent increase in incidence, are fentanyl (synthetic opioids)
and heroin (Hoots & Seth, 2018). From 2006 to 2013, overdose deaths from synthetic
opioids (fentanyl and tramadol) remained statistically unchanged (0.9 per 100,000
persons in 1999 to 1.0 per 100,000 persons in 2013); then from 2013 to 2016 synthetic
opioid death jumped by an average of 88% per year (Hoots & Seth, 2018; Hedegaard et
al., 2017). In a single year, from 2015 to 2016, rates of overdose deaths from synthetic
opioids had a two-fold increase from 3.1 to 6.2 per 100,000 persons (Hoots & Seth, 2018;
Hedegaard et al., 2017). Overdose deaths from heroin have increased from 1.9 per
100,000 persons in 2012 to 4.9 per 100,000 persons in 2016 (Hedegaard et al., 2017).
These statistics highlight the importance of healthcare providers being knowledgeable
and confident in safe opioid prescribing to prevent long-term use, abuse, addiction, and
potential overdose.
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Opioid Guidelines
Evidence has shown that substantial risk is involved with treating chronic and
acute pain with opioid medications (Dowell et al., 2016). In 2016, CDC released
guidelines for healthcare providers on initiating, selecting, dosing, and assessing risks of
opioid prescribing to inform healthcare providers on safe and evidence-based opioid
prescribing (Dowell et al., 2016).
Prescribing
Initially, when deciding if an opioid prescription is indicated for chronic pain, a
healthcare provider should assess if prior pain management attempts with non-opioid
therapy were used and if they failed to provide pain relief (Dowell et al., 2016). The
type, duration, and dose are very important factors when prescribing opioids. CDC
recommends an immediate-release opioid rather than an extended-release medication
(Dowell et al., 2016). Initial opioid prescriptions should also be the lowest dose that is
effective (Dowell et al., 2016). Prescriptions exceeding 50 MME per day should be
carefully scrutinized and prescriptions exceeding 90 MME per day should be rare and
have substantial reasoning to back up its use (Dowell et al., 2016). If opioids are
prescribed for acute pain, they should be kept to as low of a dose as possible, prescribed
as immediate-release opioids, and opioid therapy should not last longer than seven days,
with three days being ideal treatment duration (Dowell et al., 2016). If opioid therapy has
progressed to durations longer than the acute phase, between one week and four weeks,
healthcare providers should discuss the risks and benefits again with patients (Dowell et
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al., 2016). A risk-benefit discussion should be repeated again if opioid therapy continues
past three months (Dowell et al., 2016).
Healthcare providers should also assess the patient for risk factors that may
predispose the patient to potential opioid abuse (Dowell et al., 2016). These risk factors
can include current benzodiazepine use, need for higher doses, or substance abuse history
(Dowell et al., 2016). Moreover, healthcare providers might consider naloxone
prescriptions for higher risk patients (Dowell et al., 2016). Naloxone has shown to
reverse the inhibition of respiratory drive that develops during an opioid overdose (Chou
et al., 2017). Prior to starting treatment, healthcare providers need to search for the
patients via state prescription drug monitoring programs to determine if they have any
other opioid prescriptions elsewhere or are currently on medications that might be
harmful while on opioids (Dowell et al., 2016). Additionally, healthcare providers should
also be prepared to offer medical treatment for opioid use disorder (buprenorphine or
methadone) when indicated (Dowell et al., 2016). Finally, it is recommended that
healthcare providers use their discretion in assessing the need for urine drug screening to
determine proper opioid prescription use and/or if there exists illicit drug use on a caseby-case basis (Dowell et al., 2016).
Patient Education
As with all medications or treatments, the risks and benefits of opioid use should
be thoroughly addressed and explained in detail to the patient prior to initiating treatment
(Dowell et al., 2016). Healthcare providers have a duty to the patient to have shareddecision making discussions while reviewing the patient’s goals in terms of pain
management and functionality while on opioid therapy (Dowell et al., 2016). The
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patient’s goals should be written into a treatment plan with inclusion of the when and
how of opioid therapy discontinuation, whether the pain management goals have been
met, and/or whether the risk of continued use outweighs the benefits (Dowell et al.,
2016). If opioid therapy is determined to be indicated for protracted use, the healthcare
provider should schedule office visits at regular intervals, to again discuss the risks and
benefits of continuing opioid use (Dowell et al., 2016). This guidance to maintain a
continuous dialog between healthcare providers and patients is to ensure safe and
effective management of opioid treatment.
Opioid Knowledge, Confidence, Concern
Healthcare providers’ knowledge of opioid prescribing practices is key to
reducing preventable opioid abuse. Multiple studies have surveyed healthcare providers’
confidence in prescribing opioids, and consistently reveal that the majority of healthcare
providers report diminished confidence in or felt unprepared to prescribe opioids for
chronic pain (Darer et al., 2004; Jamison et al., 2014; Pearson et al., 2017; Pohler &
Nowak, 2017). A study by Pearson et al. (2017) found that 60.8% healthcare providers
responded negatively to being asked if they felt confident to manage chronic pain
patients. While confidence was low, a majority (55.1%), of the same respondents
reported having a concern for opioid addiction in their patients (Pearson et al., 2017).
This demonstrates the perceived importance healthcare providers have of proper opioid
management despite a lack of knowledge. One important finding reported by Pearson et
al. (2017) noted that when healthcare providers reported following an opioid clinical
practice guideline it correlated with increased confidence. Clinical practice guidelines
are recommendations developed for healthcare providers based on the best available
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evidence (i.e., CDC opioid guidelines) that better direct patient care (Shekelle, 2018).
While the aforementioned surveys have explored healthcare providers’ confidence, it is
unclear the knowledge, confidence, and concern PAs possess when prescribing opioids.
In research presented at the annual American Academy of Physician Assistants
(AAPA) conference in 2017, Pohler & Nowak (2017) found that when asking practicing
PAs how they felt their training prepared them for identifying opioid abuse and the
evaluation and management of pain, they responded with average scores of 2.89 and 2.99
respectively on a five-point Likert scale (Pohler & Nowak, 2017). PA students also
reported that their education did not prepare them to evaluate and manage pain (3.20 out
of 5) or to identify opioid abuse (2.89 out of 5) (Pohler & Nowak, 2017). This reported
lack of confidence and feeling that their training did not prepare them, demonstrates the
need for further education and training for PAs and PA students.
Conclusion
The medical treatment process for controlling pain via opioid medications is a
common therapy that involves substantial risk (Hoots & Seth, 2018; Chahl, 1996; Shah et
al., 2017). One aspect that might be contributing to long-term opioid use and abuse is
healthcare provider prescribing habits (Shah et al., 2017). Healthcare providers have
consistently reported lacking the knowledge and confidence to manage chronic pain or
identify opioid abuse, including PAs (Darer et al., 2004; Pearson et al., 2017; Pohler &
Nowak, 2017). Healthcare providers who do report higher confidence levels were more
likely to use clinical practice guidelines to direct patient care (Pearson et al., 2017).
Therefore, CDC opioid prescribing guidelines might be an effective tool to improve
education and confidence in PA students.
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The following chapter will include methodology of this research study. The
research questions will be restated along with identifying the study population and
description of the pre- and post-assessment instrument with some of the included
questions. The study design and procedures will be thoroughly described to allow for the
methods to be repeated. Lastly, a discussion of the validity and reliability of the pre- and
post-assessment instrument, how the data will be analyzed, and the anticipated limitations
will also be included in the next chapter.
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Chapter 3: Methodology
Introduction
The purpose of this study was to evaluate the levels of knowledge, confidence,
and concern of Bethel University PA 2020 cohort with respect to opioid prescribing
methods and strategies for the medical treatment and clinical management of pain. There
is insufficient research concerning PA student’s knowledge, confidence, and concern in
the matter of prescribing opioids. Therefore, this research study investigated and
analyzed the following research questions:
1.

How is PA student knowledge increased following completion of the CDC
opioid prescribing module training?

2.

How is PA student opioid prescribing confidence increased following the
completion of the CDC opioid prescribing module training?

3.

How is PA student concern affected with respect to opioid prescribing
before and after completion of the CDC opioid prescribing module
training?

The remainder of this chapter will address the study population, instrumentation,
procedures, validity and reliability, data analysis, limitations, and conclusion.
Study Population
The participant population of this research study included a convenience sample
of 28 members of the Bethel University PA program 2020 cohort. The two primary
researchers, who were also members of the Bethel University PA program 2020 class,
were excluded from the study. Permission to utilize the selected participants stated above
and proceed with the research study was granted by PA professor, Cindy Goetz PA-C
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(Appendix A). Bethel University Level 3 Institutional Review Board (IRB) approval of
the research study was granted by Wallace Boeve, EdD, PA-C, Bethel University PA
program director (Appendix D).
Instrumentation
This study utilized a pre- and post-assessment evaluation created by the
researchers, which contained a total of 17 multiple choice questions to assess opioid
prescribing knowledge and two questions with a 10-point Likert scale (0 - indicates no
confidence or concern; 5 indicates average confidence or concern; 10 - indicates
complete confidence/significant concern) evaluating the levels of confidence and
concern, individually, when prescribing opioids (Appendix C). A higher score on the
confidence scale indicated greater confidence in prescribing opioids. A higher score on
the concern scale indicated greater concern with prescribing opioids. The 17 multiple
choice questions to assess knowledge levels were developed based on nine of 12 modules
of CDC’s opioid prescribing training – Applying CDC’s Guidelines for Prescribing
Opioids: An Online Training Series for Providers – found on CDC’s website (CDC’s
guidelines for prescribing opioids, 2017). The opioid topics evaluated in the assessment
evaluations are non-pharmacological treatment of chronic pain, opioid side effects,
patient-rated outcome measures, patient follow-up care, opioid-use disorder, opioid-use
disorder risk factors, overdose risk factors, MME, tapering opioids, benzodiazepines,
prescription drug monitoring programs, urine drug testing, and medical assisted
treatment. Both the pre- and post-assessment evaluations were identical and created
through the testing platform, eMedley (https://he.emedley.com).
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Procedure
This is a descriptive quantitative study involving evaluation via pre- and postassessment evaluations of opioid prescribing knowledge for chronic pain and levels of
confidence and concern in prescribing opioids. Study participants completed the preassessment evaluation during the initial months of the clinical year after completion of
their didactic education to establish baseline opioid prescribing knowledge, level of
confidence, and level of concern. Following the pre-assessment evaluation, participants
completed nine of the eleven modules of the CDC opioid prescribing training – Applying
CDC’s Guidelines for Prescribing Opioids: An Online Training Series for Providers.
Two of the 11 modules were omitted from this research study due to the content existing
outside the scope of purpose of this research. During the implementation of this study,
CDC created a 12th module pertaining specifically to nurse practitioners. That module
was as not included in the research study. After completion of the CDC opioid
prescribing module training, participants completed a post-assessment evaluation to
assess opioid prescribing knowledge, confidence, and concern. The pre- and postassessment evaluations were distributed electronically via the Bethel University PA
program eMedley website as part of PA Professional Practice Capstone completed in the
fall semester of 2019. Informed consent (Appendix B) was provided to each of the
participants prior to the pre- and post-assessment evaluations. Additionally, each
participant was given the option to decline consent of their responses to both the pre- and
post-assessment evaluations being included in the study. All contact for the participants
to perform the assessments came from Cindy Goetz PA-C, instructor for the PA
Professional Practice Capstone course and Lisa Naser PA-C, Research Coordinator.
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Pre-assessment evaluation, CDC opioid prescribing module training, and postassessment evaluation were assigned to the participants to be completed during two-week
blocks. The completion schedule commenced as outlined in Table 1.
Table 1
CDC Module Schedule for PA Professional Practice Capstone
Weeks

Modules & Assessments

Assignment

1–2

Pre-assessment evaluation on eMedley
Available 8/19/19; closed 8/30/19

Complete pre-assessment
evaluation (due
8/30/19)

3–4

1. Addressing the Opioid Epidemic:
Recommendations from CDC

Submit completion
screenshot (due
9/13/19)

2. Treating Chronic Pain Without Opioids

Submit completion
screenshot (due
9/27/19)

5–6

7–8

9 – 10

11 – 12

13

3. Communicating with Patients
4. Reducing the Risks of Opioids
5. Addressing Opioid Use Disorder
6. Dosing & Titration of Opioids: How
much, How Long; How & When to
Stop
7. Determining Whether to Initiate
Opioids for Chronic Pain
9. Opioid Use & Pregnancy
10. Motivational Interviewing
Post-assessment evaluation on eMedley
Available 11/11/19; closed 11/22/19

Submit completion
screenshot (due
10/11/19)
Submit completion
screenshot (due
10/25/19)
Submit completion
screenshot (due
11/8/19)
Complete post-assessment
evaluation (due
11/22/19)

Note. The first module was assigned for completion during the third and fourth weeks of
fall 2019 semester and then two modules were subsequently assigned to be completed in
two-week blocks.
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The participants had the capability to work in advance and complete the modules
at their own pace ahead of the assigned time frame. The pre-assessment evaluation was
required to be completed by the participants during the time period 8/19/2019 to
8/30/2019, and completion of the post-assessment evaluation was required between the
period 11/11/2019 to 11/22/2019. Participant pre- and post-assessment evaluation data
was de-identified by Bethel University PA program Research Coordinator, Lisa Naser
PA-C. The electronic de-identified data was then given to the researchers for data
analysis and was then uploaded into IBM analytics software, SPSS, listing each
participant’s de-identified pre- and post-assessment evaluation results. This data was
then stored on both the researchers’ password protected computers for the duration of
data collection and analysis. Upon completion of the study, all electronic data pertaining
to the participants involved in the research was purged from the researchers’ computers
and stored on an external storage device locked in the PA program office for a minimum
of five years, per securing requirements for Bethel University’s PA Program.
Validity and Reliability
The researchers that executed this study created the questions for the pre- and
post-assessment evaluations. In order to assess the content quality and readability of the
questions found on the pre- and post-assessment evaluation, the questions were sent to
and appraised by an expert review panel consisting of a medical doctor specializing in
addiction medicine, two PA pain clinic providers, and a Bethel University PA faculty
member. The pre- and post-assessment evaluation was revised accordingly to the advice
and feedback given by the expert panel. The modifications consisted of amending
grammatical errors and dosage inconsistencies. One expert disagreed with the question
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regarding birth defects; however, the researchers elected to not omit this question as it
was obtained and adapted from a specific self-learning assessment included in the CDC’s
opioid training modules.
In addition to the individuals above, a pilot group of 12 recent graduates of the
Bethel University PA program completed the knowledge assessment to determine the
quality of the assessment questions. Item statistics of the knowledge questions were
evaluated and analyzed. Refer to Table 2.
Table 2
Opioid PA Graduate Quality Assessment Item Analysis
Question
No.

Total

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17

100.00%
58.33%
16.67%
100.00%
100.00%
75.00%
91.67%
100.00%
75.00%
33.33%
100.00%
91.67%
100.00%
100.00%
91.67%
91.67%
58.33%

Correct Group Response
Upper 27%
Lower 27%
100.00%
66.67%
66.67%
100.00%
100.00%
66.67%
100.00%
100.00%
100.00%
66.67%
100.00%
100.00%
100.00%
100.00%
100.00%
100.00%
66.67%

100.00%
0.00%
0.00%
100.00%
100.00%
66.67%
100.00%
100.00%
66.67%
0.00%
100.00%
100.00%
100.00%
100.00%
100.00%
66.67%
33.33%

Point
Biserial
0
0.26
0.53
0
0
0.34
0.18
0
0.34
0.71
0
0.18
0
0
-0.25
0.18
0.5

Note. The reliability coefficient (KR20) of the assessment was 0.16. The highest score
was 17/17 and the lowest score was 12/17 with the median of 13.50 and mean of 13.83.
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No changes to the assessment evaluation were made to the assessment knowledge
questions based on the point biserial given the small sample size. This quality
assessment group of graduate PA students also did not complete the CDC opioid
prescribing training.
The validity and reliability of the instrument utilized in this study was not
established prior to data collection.
Data Analysis
Following data collection, the researchers analyzed the data using SPSS (SPSS
INC. Version 25). The independent variable was CDC’s opioid prescribing module
training – Applying CDC’s Guidelines for Prescribing Opioids: An Online Training
Series for Providers – at two time points (pre-assessment and post-assessment). The
dependent variables were opioid prescribing knowledge score, confidence level for
prescribing opioids, and level of concern for prescribing opioids. Each dependent
variable was analyzed using independent paired t-tests with a significance level set at p <
0.05.
Limitations
The limitations of this research included a small and narrow participant
population, the potential for a learning effect, and the lack of a validated assessment
instrument. This study only sampled 28 members of the 2020 Bethel University PA
program cohort, which is not representative of all current PA students. Therefore, the
results had a limited ability to be generalized across the broader population of PA
students besides the 2020 Bethel University PA program cohort. Additionally, since the
pre- and post-assessment evaluations were taken within a short time span there leaves the
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possibility for a learning effect. Finally, the researchers used a self-developed instrument
to determine knowledge based on beliefs of what would be essential PA opioid
prescribing knowledge for a graduating PA student or PA student taking the physician
assistant national certification exam (PANCE). Utilizing an unvalidated instrument to
evaluate knowledge limits the ability to detect and determine clinically and statistically
meaningful change.
Conclusion
This methodology allowed for assessment of the baseline opioid prescribing
knowledge, confidence, and concern of the Bethel University PA 2020 cohort following
completion of didactic education and after completion of CDC’s opioid prescribing
module training. With this research, there are opportunities to assess how current PA
program curriculums prepare students to appropriately prescribe opioids. The following
chapters will review the results of the assessment, statistical analysis, and discussion of
the results. Furthermore, the following chapters will discuss the potential future research
opportunities associated with this research.
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Chapter 4: Results
Introduction
This chapter comprehensively includes and reviews the results and analysis of
data collected from pre- and post-assessments. The researchers utilized a self-developed
pre- and post-assessment evaluation (Appendix C) with the intent to determine how
knowledge, confidence, and concern for the prescribing of opioids in Bethel PA students
after utilizing CDC’s opioid prescribing modules. The intention of this chapter was to
gather, analyze, and compare pre- and post-assessment scores from each dependent
variable – knowledge, confidence, and concern.
Participants
There were a total of 28 Bethel University PA students from the class of 2020
who initially participated in the pre- and post-assessment evaluations. In order to be
eligible, participants had to complete the pre-assessment evaluation between 8/19/2019
and 8/30/2019 and the post-assessment evaluation between 11/11/19 and 11/22/19. One
participant failed to complete the pre-assessment evaluation within the required pre-test
time frame. At the participant’s request, the pre-assessment evaluation was made
available again in the eMedley testing platform after 8/30/2019 by the research
coordinator, and the participant completed the pre-assessment evaluation one day later.
Another participant failed to complete the post-assessment evaluation even with the time
frame for completion for this participant was extended by one week; therefore, the preassessment evaluation result of this participant was removed and not included in the final
analysis. Thus, the pre- and post-assessment evaluations of 27 out of 28 Bethel
University PA students were used in this study.
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Data Analysis
Independent paired t-tests were conducted on each of the dependent variables:
knowledge score, level of confidence, and level of concern to compare the pre- and postresults of the pre- and post-assessment evaluations completed by each of the participants.
Significance level was set at p < 0.05. For all unexpurgated data of the pre- and postassessment evaluations, including SPSS output data, refer to Appendix E.
Knowledge Score
The average pre-assessment evaluation score was 12.26 ± 2.25 out of 17, with the
average post-assessment evaluation score of 14.96 ± 1.58 out of 17. Participants percent
correct for pre-assessment scores was 72.11% ± 13.21, and the post-assessment percent
score was 88.02% ± 9.30. There was a statistically significant improvement between the
pre- and post-assessment evaluation scores t(26) = 6.55, p = 0.00. Knowledge scores of
the pre- and post-assessment evaluation are represented in Figure 4.
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Figure 4
Knowledge Scores (averages) of Pre- and Post-Assessment Evaluations of CDC Opioid
Training of PA Students.
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Pre-assessment

Post-assessment

Level of Confidence
Participants reported a pre-assessment confidence level of 3.70 ± 2.00 out of 10,
and a post-assessment confidence level of 5.89 ± 1.42 out of 10. There was a significant
increase in confidence level on prescribing opioids between the pre- and post-assessment,
t(26) = 4.73, p = 0.00, which indicates the participants gained more confidence with
prescribing opioids.
Level of Concern
Participants reported a pre-assessment concern with prescribing opioids of 7.18 ±
1.9 out of 10 and a post-assessment concern with prescribing opioids of 5.52 ± 1.78 out
of 10. There was a significant decrease in the level of concern with prescribing opioids
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from pre- to post-assessment, t(26) = – 4.60, p = 0.00. This indicates that participants
reported less concern with prescribing opioids following CDC’s opioid prescribing
modules. Figure 5 illustrates the levels of confidence and concern.
Figure 5
Confidence and Concern Levels of PA Students Before and After Completing CDC
Opioid Training.
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Conclusion
The primary aim of this research project was to assess if completing CDC’s
opioid prescribing training modules – Applying CDC’s Guidelines for Prescribing
Opioids: An Online Training Series for Providers – improved knowledge and had an
effect on the level of confidence or concern of Bethel University PA students when
prescribing opioids. The study results demonstrate that through knowledge improvement,
an increase in confidence and a decrease for concern, the modules likely created a
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statistically significant result among Bethel PA student participants. Further
investigation with a larger sample size would be recommended to determine validity of
conclusions through use of a larger sample population. A thorough overview and
comprehensive discussion of the findings in this chapter, as well as implications and
recommendation for future research will continue in chapter five.
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Chapter 5: Discussion
Introduction
This final chapter comprises a discussion of the results, interpretation,
implications, limitations, and conclusions of the research study conducted regarding how
knowledge, confidence, and concern for the prescribing of opioids in Bethel PA students
is affected after completing CDC’s opioid prescribing training modules. This chapter
will elaborate on what the findings in this research study might mean for PA education
moving forward, particularly how the study’s findings could potentially influence PAs
practicing and prescribing opioids. Moreover, factors such as population size, lack of
diversity, and study design will be addressed. Finally, this chapter will also extrapolate
practical actions and recommendations for exploring further research.
Discussion of Findings
The objective of this study was to assess if CDC’s opioid prescribing training
modules improved knowledge, increased level of confidence, or had an effect on level of
concern when prescribing opioids. The study results suggest that CDC’s opioid
prescribing training modules significantly improved opioid prescribing knowledge as
assessed by the created pre- and post-assessment evaluations in this study. The
participants scored an average of 12.26 ± 2.25 out of 17 on the pre-assessment evaluation
and 14.96 ± 1.58 out of 17 on the post-assessment evaluation, which represents an
increase in 2.7 correct answers or 15.9% improvement. This is an encouraging finding as
healthcare providers report having a lack of knowledge in managing opioid therapy to
treat chronic pain and supports the notion that CDC’s opioid prescribing training modules
effectively increase opioid prescribing knowledge (Darer et al, 2004, Pearson et al, 2017).
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PA students, specifically, have reported feeling unprepared to manage chronic pain.
From this, it further highlights the benefits that can be provided through CDC’s opioid
prescribing training modules, or other additional education, which then could be
implemented into current, formal curriculums (Pohler & Nowak, 2017). What is unclear
is how this increase in 2.7 correct answers between the pre- and post-assessment would
translate to clinical practice and an improvement in clinical outcomes.
The research study data also illustrates that PA student confidence significantly
increased after completion of CDC’s opioid prescribing training modules. The increase
went from 3.70 ± 2.00 out of 10 on the pre-assessment evaluation to 5.89 ± 1.42 out of 10
on the post-assessment evaluation. While there was an increase of 2.19, the pre- and
post-assessment confidence levels were both still low on the 10-point likert scale.
Additional information of confidence levels of medical providers within other specialties
that also have different levels of experience would give these seemingly low confidence
scores more context. Prior research has found that PA students reported low confidence
levels in regard to managing chronic pain; thus, low confidence scores might be expected
as students still completing their education and training are less confident overall with
their medical knowledge and skills (Pohler & Nowak, 2017). Findings in prior research
showed that providers who reported following a set of guidelines for opioid therapy
management correlated with increased levels of confidence (Pearson, 2017). This further
highlights the essential role that CDC’s opioid prescribing training modules may provide
since they are structured around the 2016 CDC guidelines on opioid prescribing.
Finally, the results demonstrated that PA student concern significantly decreased
from 7.18 ± 1.9 to 5.52 ± 1.78 out of 10 between the pre- and post-assessments, which
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represented a decrease of 1.66. This finding may indicate that when knowledge and
confidence are both low, levels of concern may be high. Alternatively, as more
knowledge and confidence were obtained the concern for prescribing opioids decreased.
Furthermore, this finding is supported by prior research. Pearson (2017) suggested that
when medical provider confidence was low, there was a correlation with increased
concern about opioid prescribing.
Limitations and Recommendations for Further Research
Pursuing further research to expand on this study and hypotheses to include future
and past Bethel University PA cohorts would be advantageous in order to evaluate any
potential changes in curriculum regarding knowledge, confidence, or concern related to
opioid prescribing. While this study was limited by sample size (28 Bethel University
PA students), further research is recommended to include additional PA students from
other PA programs in Minnesota, as well as other programs throughout the United States.
This would allow for a more diverse participant pool to be obtained and for the
participants to be representative of the entire cohort of PA students. With the addition of
a larger sample set, future investigations may also explore study designs that include a
control group versus a single or multiple experimental group so as to improve
observation of correlation and differences under more strict conditions while controlling
for threats of validity and minimizing possible bias, confounders, and misplaced
assumptions. Additionally, it would be beneficial for the research instrument (i.e., preand post- assessment evaluation), to be officially validated in order to enhance the ability
to detect and determine clinically and statistically meaningful change.
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Furthermore, follow-up assessments of Bethel University PA students could be
conducted in order to evaluate changes in knowledge, confidence, and concern as
students progress into their careers and specialize in other areas of medicine. Repeat
completion of the post-assessment evaluation at different future time points would give
insight into how well the improvement in knowledge of the participants maintains
overtime as well.
More importantly, subsequent steps with this research would be to evaluate how
CDC’s opioid prescribing training modules affect the habits of clinical providers when
prescribing opioids, one, two, and/or five years into practice. This study data narrowly
represents an academic assessment of knowledge, while the vital and fundamental
assessment of healthcare is in clinical outcomes. Later research could also assess PAs
before and after completing CDC’s opioid prescribing training modules. Data may then
be collected and analyzed for opioid prescribing practices at future time points. The
potential clinically meaningful outcome hypothesis may be: Does CDC’s opioid
prescribing training modules change clinical practice? This research study found that
knowledge and confidence improved, while concern decreased. However, the data gives
no inference to the future clinical prescribing outcomes of the 28 participants involved in
this study.
Conclusions
This research study demonstrates that when the class of 2020 Bethel University
PA students completed CDC’s opioid prescribing training modules there were significant
increases in knowledge, confidence, and decreases in concern. This investigation also
represented an initial assessment of the knowledge, confidence, and concern of Bethel PA
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students following completion of their didactic education based on what the research
team considered fundamental for a graduating PA student. Thus, the findings from this
research may provide the Bethel University PA program with an opportunity to integrate
additional training into the curriculum with the ability to also assess potential changes
and improvements. These research findings also suggest that CDC’s opioid training
modules may increase the knowledge and confidence and decrease concern in other
medical students and medical providers.
Ultimately, the key objective of current and future healthcare providers when
addressing pain management in patients, should be to provide effective and safe pain
treatment strategies while simultaneously minimizing the risk of opioid misuse, abuse,
overdose, and possible death. Clearly, this goal is achieved primarily through appropriate
opioid prescribing methods and guidelines. Therefore, CDC’s opioid prescribing training
modules may play an integral role in preparing PA students as they enter into practice
where it is likely that responsible patient care involving the treatment and management of
pain with opioid therapy will be necessary.
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Opioid Knowledge, Confidence, and Concern Research Informed Consent
The United States has a significant health concern regarding the use of opioids.
As future medical providers, it is important to learn about the clinical applications and
appropriate prescribing practices of opioids; including benefits and risks. Centers for
Disease Control and Prevention (CDC) has published guidelines for prescribing opioids
for chronic pain. These guidelines are presented in 12 online training modules. Bethel
University Physician Assistant program faculty have decided that the training provided
by CDC are an excellent way to learn more about the use and prescribing guidelines for
opioids. This material is incorporated into the course PHAS735 – Physician Assistant
Professional Practice Capstone.
For this assignment, you will take a pre-assessment evaluation found on the
testing platform, eMedley. You will then complete each of the assigned modules within
the specified timeframe as outlined by the course’s instructor. Upon completion of the
modules, you will complete a post-assessment evaluation. All test scores will be
recorded from eMedley to Moodle by the instructor of the course.
We, Travis Williams and Lealand Torgerson, are investigating the knowledge,
confidence levels, and concern of prescribing practices of opioids before and after
completing CDC’s opioid prescribing training modules. We hope to learn how
knowledge, confidence levels, and concern change before and after completion of CDC’s
opioid prescribing training modules.
You were selected as a possible participant in this study because you are required
to complete CDC’s opioid prescribing training modules as a part of PHAS735 PA
Professional Practice Capstone during the fall semester of 2019.
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Participation in this research involves allowing your pre- and post- assessment
evaluation scores to be used by the researchers for data analysis. You will complete the
pre-assessment evaluation, nine of 12 CDC opioid prescribing training modules, and the
post-assessment evaluation as required by the course instructor. If you choose to allow
your scores to be utilized for this research, your pre- and post-assessment evaluation
scores will be deidentified by the course instructor, and the researchers will receive a
database with scores listed in a randomized order. There will be no way for the
researchers to link you to your exam scores and your confidentiality will be maintained.
The researchers will not be able to access your scores within the testing platform; only
the course instructor will have this capability. No one will be identified or identifiable in
any written reports or publications. Only aggregate data will be presented.
Your decision whether or not to participate will not affect your future relations
with Bethel University PA program, faculty, or cohort in anyway. If you decide to allow
your scores to be utilized and then change your decision, you may contact the course
instructor at any time prior to the close of the study's data collection to withdraw from the
study.
This research project has been reviewed and approved in accordance with Bethel
University’s Levels of Review for Research with Humans. If you have any questions
about the research and/or research participants’ rights or wish to report a research related
injury, please contact:
Lealand Torgerson PA-S, Researcher, l-torgerson@bethel.edu
Travis Williams PA-S, Researcher, travis-williams@bethel.edu
Lisa Naser PA-C, Research Chair, l-naser@bethel.edu
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By selecting “Yes” below, you are providing your consent for your anonymous
responses to be utilized for this research study. Completing course activity is mandatory
but allowing the use of your data or inclusion into this research project is your choice.
You may withdraw your permission for the researchers to use your pre- and postassessment evaluation scores at any time prior to the close of the studies data collection.
Choosing to not allow your data to be used in future publications will not affect your
current or future relations with Bethel University PA program in anyway.

I agree to allow my pre-assessment and post-assessment scores to be used for this
research study.
A. No, I do not allow my pre-assessment and post-assessment scores to be used for
this research study.
B. Yes, I allow my pre-assessment and post-assessment score to be used for this
research study.
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Opioid Pre- and Post-Assessment Evaluation
Scenario #1
Joe is a 29-year-old male who presents to the family practice clinic requesting
pain relief. For the last six weeks, Joe has had 6/10 pain located along the width of his
low back, just superior to his pelvis. He denies any injury or trauma; he thinks that he
hurt his back shoveling snow. He has been using heat alternating with ice and ibuprofen
800 mg TID with minimal relief. Joe denies any radicular symptoms and bowel/bladder
changes. He denies any fever, chills, or weight loss. He is up to date on his preventive
health care needs. He has not had any back surgeries. He does not use tobacco, alcohol,
or recreational drugs.
On physical exam, he has reduced ROM with flexion and extension. He has full
strength of the lower extremity bilaterally. He has no deficits in sensation to the lower
extremity bilaterally. Patellar and Achilles tendon reflexes are 2+ bilaterally. Negative
straight leg raise.
Joe works for a company in the shipping department and he does a lot of bending,
lifting, and twisting. He is having trouble performing his job because of his back pain.
He also has trouble finding a comfortable position to sleep in at night.
1.

What is the next best treatment for Joe?
a. Joint injection at L5-S1
b. Physical Therapy
c. Acetaminophen (Tylenol) 1,000 mg every 3 hours instead of ibuprofen
d. Acetaminophen (Tylenol) with codeine 1 tablet at bedtime
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Post-assessment explanation: Use non-pharmacologic and non-opioid treatments
whenever possible and utilize non-pharmacologic and non-opioid first line for acute
pain. Consider the use of opioid pain medication if the risk of pain outweighs the risk of
the opioid medication. Acetaminophen 1,000 mg every 3 hours equals 8,000 mg per 24
hours, which is over the maximal recommended dose of acetaminophen. Use other
modalities prior to initiating narcotics such as codeine. Joint injections and aspirations
are great treatments for acute pain; however, this patient has MS pain and not pain
stemming from his spine (Module 1: CDC Recommendations: #1, 2, 3; Module 2).
Joe is seeing you for his follow up appointment. He reports that he has attended 6
weeks of physical therapy. He is able to do his job better, but his pain is still a 6/10 and
he continues to have problems sleeping. Joe would like to try an opioid to help with
sleep and to decrease his overall pain.
2. All of the following statements are true regarding the start of opioid therapy
except?
a. Consider how therapy will be discontinued if benefits do not outweigh
risks.
b. Providers should discuss expectations of 100% pain reduction.
c. Providers should establish treatment goals with the patient.
d. Opioid therapy is continued if pain reduction outweigh the medication risks.
Post-assessment explanation: All of the statements are consistent with the CDC’s goals
for chronic pain reduction and improvement in function with the use of opioids except
there is rarely 100% reduction of pain. A more reasonable goal is to be able to meet
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functional goals with a reasonable amount of pain (Module 1: CDC Recommendations:
#2, Module 3).
3. Why should a provider check the prescription drug monitoring program (PDMP)?
a. To assess for the use of illicit substances that would increase the risk for
overdose.
b. To dismiss your patient from your practice if he/she has been receiving
prescriptions from other prescribers.
c. To look for dangerous combinations of controlled substance
prescriptions that would increase risk for overdose.
d. To monitor for drug diversion that you are suspicious is happening with
this patient’s prescriptions.
Post-assessment explanation: A prescription drug monitoring program (PDMP) is an
electronic database specific to each state that allows clinicians and pharmacists to track
controlled substance prescriptions for a patient that would put a patient at risk for
serious harm including overdose. The PDMP does not help a clinician to look for illicit
substances, you would need a urine drug test. It is not recommended by CDC that
patients be dismissed from practices; rather, providers should use this encounter to
assess for safety and prescribe naloxone. The PDMP can only tell the clinician that a
prescription has been filled, not if the medication has been ingested or diverted (Module
1: CDC Recommendations: #9, 10).
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4. You decide to prescribe an opioid for Joe. Which of the following medications
would you prescribe for chronic pain that has not improved his function at work
with non-pharmacologic therapies?
a. Hydrocodone/APAP 5/325 mg 1 tablet PO BID PRN pain
b. Hydrocodone/APAP 10/325 mg 1 tablet PO BID PRN pain
c. Methadone 5 mg 1 tablet PO Q 6 hours
d. Oxycodone ER (Oxycontin)10 mg 1 tablet PO TID
Post-assessment explanation: When first prescribing an opioid for chronic pain CDC
recommends that the clinician “begin with immediate release opioids, use the lowest
effective dose, evaluate benefits and harms frequently, and use strategies to mitigate
risk.” Oxycodone ER is a long acting opioid which would not be appropriate for a
starting medication. Methadone is used for medication assisted therapy for opioid use
disorder in a specialty clinic, and in some complex analgesic regimens. It is not
appropriate as a starting medication. Hydrocodone/APAP is a short acting, low potency
opioid (combined with acetaminophen) and you would use the lowest starting dose of
5/325 mg (Module 1: CDC Recommendations: #4, 5, Module 7).
5. Which of the following is an expected side effect of opioid medications?
a. Diarrhea
b. Drowsiness
c. Salivation
d. Tachypnea
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Post-assessment explanation: Side effects of opioids include constipation, dry mouth,
nausea, vomiting, drowsiness, confusion, tolerance, sexual dysfunction. The only correct
answer is drowsiness (Module 1: CDC recommendation #8).
6. You prescribe a short acting opioid medication at its lowest dose for Joe. This is
the first time your patient has taken opioids. What time frame best represents the
CDC’s recommended time for follow up for your patient?
a. 5 days
b. 14 days
c. 2 months
d. 3 months
Post-assessment explanation: CDC recommends that clinicians should re-evaluate the
effects of short acting opioid therapy and assess risk in 1-4 weeks after prescribing the
medication. There should be repeated follow up at least every 3 months with assessments
of functional benefit, adverse effects (including aberrant use or diversion), and safe
administration. As the dose is increased or the short acting medication is changed to a
long acting opioid, the frequency of follow up is increased (Module 1: CDC
recommendation #7, Module 3).
Scenario #2
You are working in the emergency department and caring for Mrs. Adams, a 57year-old female who has a non-displaced fracture of the proximal 5th metatarsal. You
have put her in a posterior short leg splint and referred her to podiatry.
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1. What medication would you send your patient home with for pain control?
a. Oxycodone/APAP 5/325; 1 po bid prn pain #14
b. Oxycodone/APAP 10/325; 1 po bid prn pain #10
c. Oxycodone ER 5 mg; 2 po bid prn pain #20
d. Oxycodone ER 10 mg; 1 po bid prn pain #20
Post-assessment explanation: For acute pain that is expected to last for a short period of
time, CDC recommends that a short acting opioid be prescribed at its lowest effective
dose for the expected time of pain due to the injury. This time period is rarely expected
to be longer than 7 days. Oxycodone ER is a long acting opioid which is not appropriate
for acute pain. While the oxycodone/APAP 10/500 mg has a lesser quantity, it is a higher
dose. Oxycodone/APAP 5/500 mg is the lowest dose that would be expected to help with
the pain and a quantity of 14 tablets with instructions to take twice a day would be a 7day prescription (Module 1: CDC recommendation #6).
Mrs. Adams presents to you in podiatry. Mrs. Adams is having continued pain
and would like a refill of the opioid given in the ED. Mrs. Adams is currently taking
Sertraline 50 mg for anxiety and uses a CPAP at night. You look up this patient on
Minnesota’s Prescription Data Monitoring Program (PDMP). This is the PDMP report
for your patient:
Date

Provider

Medication / Dose

5/5/2019

Dr. Bryant

Hydrocodone/APAP 5/325 mg 1 PO Q 4-6 hours PRN #14

4/21/2019

Dr. Jones

Lorazepam 2 mg 1 PO QHS #15

4/2/2019

Dr. Wu

Hydrocodone/APAP 5/325 mg 1 PO Q 4-6 hours PRN #14
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Date

Provider

Medication / Dose

3/23/2019

Dr. Jones

Lorazepam 2 mg 1 PO QHS #15

2/21/2019

Dr. Jones

Lorazepam 2 mg 1 PO QHS #15

2/6/2019

Dr. Wu

Hydrocodone/APAP 5/325 mg 1 PO Q 4-6 hours PRN #14

2/2/2019

Dr. Smith

Oxycodone/APAP 5/325 mg 1 PO Q 4-6 hours PRN #30

1/22/2019

Dr. Jones

Lorazepam 2 mg 1 PO QHS #15

2. What risk factor for opioid overdose would you be most concerned about in this
patient?
a. Generalized anxiety disorder
b. Female gender
c. Obstructive sleep apnea
d. Benzodiazepine use
Post-assessment explanation: Risk factors identified by CDC for opioid-related harm
include previous overdose, older age, medical conditions such as sleep disorders,
renal/hepatic insufficiency, depression or other mental health disorders, pregnancy,
alcohol or other substance use disorder, and medication concerns such as taking high
doses of opioids (>50 MME/day), methadone, or concurrent benzodiazepines or other
sedatives. CDC also identifies that patients who receive opioids from multiple
prescribers and the combination opioids and benzodiazepines are at a higher risk of
overdose. This patient’s PDMP report shows she is receiving benzodiazepines with
opioids and is receiving prescriptions for opioids from multiple providers. While all of
the options are risk factors for opioid-related harms, the concurrent use of
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benzodiazepines and multiple opioid prescriptions from different prescribers are the
greatest risk factors for overdose (Module 1: CDC recommendation #8, 9, Module 4).
3. The podiatrist will manage Mrs. Adams’ fracture as it heals but does not feel
comfortable prescribing her an opioid for pain. Mrs. Adams presents to her PCP
for management of her pain. Her PCP is concerned about the inconsistent use of
opioids from multiple providers. What is the next best step for Mrs. Adams’ PCP
to consider in managing her pain?
a. Ask Mrs. Adams about the opioid prescriptions from multiple
providers on the PDMP.
b. Dismissal from the practice because of a violation of a pain contract.
c. Order a urine drug screen to prove that she is taking the opioid and not
diverting the medication.
d. Discontinue the lorazepam as she needs the opioid for her injury.
Post-assessment explanation: It is never a good idea to stop benzodiazepines (lorazepam
in this example) without a detailed assessment of the pattern and chronicity of use.
Abrupt cessation of chronic daily benzodiazepines can result in significant risks
including rebound anxiety, seizure, and death. Urine drug screens are helpful to monitor
chronic opioid therapy and to evaluate for unexpected substances. Urine drug screens
are often not able to tell how or how much medication the patient is taking and cannot be
used to determine diversion. Violation of pain contracts can often result in dismissal
from a clinician’s practice. CDC believes that dismissal from a clinician’s practice can
overlook important opportunities for opioid education and potentially life-saving
interventions such as prescription of naloxone (Narcan). Establishing goals for pain and
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function are paramount to chronic pain management and offering a conversation about
your patient’s PMDP findings is a good first step (Module 1: CDC recommendation #9,
10, 11, Module 4).
Scenario #3
You are seeing a new patient who has been on chronic opioid therapy for shoulder
pain for the last 6 years. Mary is a 41-year-old female who has osteoarthritis in her left
shoulder from overuse as a young adult. She has been taking Oxycodone 10 mg 2 PO
TID for pain. Mary reports that the Oxycodone makes her head feel “fuzzy.” Mary is
home full-time and is able to complete her daily activities. Mary’s shoulder pain causes
difficulty pulling shirts over her head and styling her hair in the morning. She wants to
babysit her new granddaughter, but her son is hesitant because of the oxycodone.
1. What is the CDC’s recommended daily morphine milligram equivalent (MME)
for an initial opioid prescription?
a. ≤ 40 MME/day
b. ≤ 50 MME/day
c. ≤ 60 MME/day
d. ≤ 70 MME/day
Post-assessment explanation: Taking ≤50MME per day minimizes risk of adverse side
effects including overdose. However, there is no definitive “safe” dose. Each opioid
prescription should include an assessment of the potential benefits of the medication
against the potential harms (including chronic opioid therapy and associated risk of
withdrawal) (Module 1: CDC recommendation #8).
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2. Mary’s MME is 90 mg/day, she has symptoms from her medication, and she is
not able to meet her functional goals such as fixing her hair and caring for her
granddaughter. What is your next step in the treatment of Mary’s pain?
a. Discuss the idea of tolerance and switch Mary to a long acting opioid such
as Oxycodone ER (Oxycontin).
b. Explore other non-pharmacological treatments and begin an opioid
taper.
c. Keep Mary’s medications the same and write a prescription for Naloxone
(Narcan) as needed for overdose.
d. Stop the opioid and use an anticonvulsant such as gabapentin (Neurontin)
instead.
Post-assessment explanation: Mary’s side-effects outweigh the benefits of the opioid.
She does not have adequate pain control, is not meeting her functional goals, and has
negative drug-related consequences despite a reasonable medication trial. In addition,
Mary’s MME is above the safety threshold suggested by CDC. Increasing her
medication or switching her to a long acting opioid increases her risk of opioid-related
harms without a reasonable expectation of benefit based on the available evidence.
Maintaining Mary’s pain treatment at the same level does not help her to meet her
functional goals. Stopping the opioid abruptly will cause painful withdrawal symptoms.
Combining non-pharmacologic and pharmacologic therapies are often more successful
than pharmacologic therapies alone. Beginning an opioid taper will reduce opioid side
effects and reduce the risk of overdose. Naloxone (Narcan) is recommended for people
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who are on greater than 90 MME/day or have significant risk factors for overdose
(Module 1: CDC recommendation #11, 12).
3. What is the proper method of tapering an opioid medication?
a. Switch to a less potent opioid and maintain dose.
b. Reduce dose frequency 10% of the starting quality every day.
c. Reduce dose by 10% of the starting quantity every week/month.
d. Switch to extended release opioid to lengthen the time between doses.
Post-assessment explanation: Taper slowly by 10% of their daily opioid quantity at
baseline per week, or per month if the patient has been on opioids for years. Increase
visit frequency during this period to counsel people on pain expectations (i.e., pain will
increase transiently as they adjust to lower exogenous opioid levels) and monitor for
adverse events such as opioid overuse or illicit use if withdrawal or cravings arise. Most
opioid-related harms associated with prescription opioids occur during periods of dose
escalation AND de-escalation (Module 1: CDC recommendation #11, Module 6).
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4. Mary becomes confrontational at the thought of taking away pain medications.
She is fearful of worsening shoulder pain and she can function fine with the dose
she is taking. She has already tried physical therapy and it did not fix her
shoulder. She does not understand why her son is withholding her granddaughter
from her and would like you to talk to him. Which of the following statements is
most helpful when addressing conflict?
a. Your medication dose is so high that you are at risk for an overdose. Is
that what you want?
b. I don’t understand why you would want to stay on this medication as it
isn’t helping anyway.
c. Your physical exam is normal, as is your MRI. You don’t need any
narcotics at this time.
d. It must be scary for you to think about decreasing pain medications,
as this is how you have treated your pain for so long.
Post-assessment explanation: Principles of motivational interviewing include empathetic
statements, helps the patient to see discrepancies between the current situation and the
patient’s goals, adjusts to the patient’s resistance, avoids statements that would lead to
arguments or confrontational behavior and supports the patient’s own behavior for
change. Validating the patient’s experience by using empathy will avoid confrontation
and encourage the patient to see how the current medication dose is not consistent with
her goals. The remaining statements have the potential for increased confrontation, as
they do not express empathy or encourage the patient to engage with you in open
conversation (Module 1: CDC recommendation #2, Module 3).
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5. Which of the following are signs or symptoms of opioid withdrawal?
a. Constipation
b. Excessive sweating
c. Increased appetite
d. Pupillary constriction
Post-assessment explanation: Opioid withdrawal has a variety of symptoms, which
includes sweating. Constipation and pupillary constriction are symptoms and signs of
opioid use. Those in withdrawal have nausea and vomiting, not an increased appetite
(Module 3 & 5).
6. Medication assisted treatment (MAT) for opioid use disorder refers to the use of
methadone, buprenorphine, or long-acting naltrexone. Which of the following
statements is true regarding MAT?
a. Buprenorphine must be administered by a MAT treatment center only.
b. It is best to start a patient on Naltrexone when they are currently using
opioids.
c. Methadone has a short half-life and is considered a short acting opioid.
d. To prescribe Buprenorphine, the clinician must have a
Buprenorphine prescribing waiver.
Post-assessment explanation: Methadone is an opioid agonist that has a long half-life
(24-36 hours) and has inconsistent bioavailability. Methadone must be dispensed by a
licensed MAT treatment center which requires that patients present at regular intervals
to receive their medication. Buprenorphine can be prescribed by any clinician who has
completed a certified training course and obtained a buprenorphine waiver from the
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DEA. Naltrexone is an opioid antagonist and will precipitate immediate withdrawal in
patients who have opioid tolerance and have opioids in their system. Patients must be
abstinent from opioids for 7-10 days if taking short acting opioids or 10-14 days if taking
long acting opioids (Module 5).
Scenario #4
Helen is a 22-year-old female G2 P0101 female who is 18 weeks pregnant. She
presents to your obstetric clinic for prenatal care. She is taking methadone 70 mg daily
and has been taking this for one year as a part of her substance use disorder treatment.
Her urine drug screen reveals the following results:
Medication / Drug

Test Result

Reference Value

Amphetamine

Negative

Negative

Barbiturates

Negative

Negative

Benzodiazepines

Negative

Negative

Cocaine

Negative

Negative

Ethanol

Negative

Negative

Methadone

Positive

Negative

Phencyclidine

Negative

Negative

Tetrahydrocannabinol

Negative

Negative

This is her second pregnancy. Her first pregnancy resulted in a premature boy
who was removed from her custody due to Helen’s active illicit substance use at the time.
Helen plans to parent the child she is expecting. Her concern today is regarding the
methadone’s effects on her pregnancy.
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1.

Which of the following is a risk to the fetus when exposed to an opioid in utero?
a. Large head circumference
b. Congenital heart defect
c. Post-term delivery
d. Hyperglycemia

Post-assessment explanation: Fetal risks associated with opioid use during pregnancy to
the fetus include: Growth restriction, abruptio placentae, preterm labor, arrhythmias,
intrauterine passing of meconium, and fetal death. There are also birth defects reported
with the use of opioids during pregnancy and these include: neural tube defects,
congenital heart defects, oral clefts, clubfoot, and gastroschisis. Large head
circumference and post-date delivery is the opposite of what could be expected with the
use of opiates during pregnancy and there is no data that reports hyperglycemia. In the
setting of an opioid use disorder, maintenance of opioid agonist therapy (methadone or
buprenorphine) is strongly recommended to optimize both short-and long-term maternal
and fetal outcomes. Congenital heart defects could be possible with the use of opioids
during pregnancy especially with use in the first trimester (Module 9).
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2. Which of the following is the best treatment option for Helen during her
pregnancy?
a. Continue the methadone and ensure she is receiving counseling for
her substance use disorder.
b. Fast taper off methadone with no subsequent use of opioids as she has no
chronic pain.
c. Refuse to care for her as you are uncomfortable with the methadone and
its pregnancy risks.
d. Switch her to naloxone from methadone as naloxone is not an opioid.
Post-assessment explanation: The fetus and the pregnant woman taking methadone do
have more risks during pregnancy. Tapering opioids during pregnancy also has risks to
the fetus and pregnant woman. It is not recommended to taper chronic use opioids
during pregnancy as the risk of substance disorder worsening with then inconsistent use
of opioids and potential for overdose is detrimental for both fetus and patient. Naloxone
is not recommended during pregnancy as there is insufficient data on its effect on the
fetus. It is recommended that pregnant women continue their methadone (or
buprenorphine) treatment during pregnancy along with psychosocial support (Module 9).
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10-Point Likert-Scale Questions
1.

What is your current confidence in the prescription of opioids for the treatment of
pain? (10 = complete confidence, 0 = no confidence)
0

1

2

3

4

No
Confidence

5

6

7

8

9

Average
Confidence

10
Complete
Confidence

2. What level of concern do you currently have in prescribing opioids for the
treatment of pain? (10 = significant concern, 0 = no concern)
0
No
Concern

1

2

3

4

5
Average
Concern

6

7

8

9

10
Significant
Concern
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